CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
调节性 T 细胞与肝细胞癌免疫逃逸：理解肿瘤微环境并推进 CAR-T 细胞治疗
英文原题：Regulatory T cells and immune escape in HCC: understanding the tumor microenvironment and advancing CAR-T cell therapy.
查看英文原题
Regulatory T cells and immune escape in HCC: understanding the tumor microenvironment and advancing CAR-T cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
肝癌最常见的类型是肝细胞癌（HCC），为全球第六大常见癌症。在HCC中，免疫系统对肿瘤细胞生长和增殖发挥关键作用。HCC可通过肿瘤微环境实现免疫逃逸，而该微环境显著促进癌症发展。本文介绍并总结肿瘤微环境中调节性T细胞（Treg）的功能和作用，重点阐述Treg如何抑制和调节免疫细胞及肿瘤细胞、细胞因子、配体和受体等的功能，从而促进肿瘤免疫逃逸。此外，文章讨论CAR-T 治疗HCC的机制，并阐述CAR-T 与Treg之间的关系。
展开英文摘要原文
Liver cancer, which most commonly manifests as hepatocellular carcinoma (HCC), is the sixth most common cancer in the world. In HCC, the immune system plays a crucial role in the growth and proliferation of tumor cells. HCC achieve immune escape through the tumor microenvironment, which significantly promotes the development of this cancer.
Here, this article introduces and summarizes the functions and effects of regulatory T cells (Tregs) in the tumor microenvironment, highlighting how Tregs inhibit and regulate the functions of immune and tumor cells, cytokines, ligands and receptors, etc, thereby promoting tumor immune escape.
In addition, it discusses the mechanism of CAR-T therapy for HCC and elaborate on the relationship between CAR-T and Tregs.
论文信息
- 作者
- Du G、Dou C、Sun P、Wang S、Liu J、Ma L
- 单位
- Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China.China
- 文献类型
- 综述
- 期刊
- Frontiers in immunology2024
- 原文标识
- PubMed 39136031 · DOI 10.3389/fimmu.2024.1431211
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →